title: Immune response to E7 protein of human papillomavirus type 16 anchored on the cell surface.
abstract: To target the E7 protein of human papilloma virus 16 to the cell surface, a fusion gene was constructed. It encodes the signal peptide, part of the immunoglobulin (IgG)-like domain, the transmembrane anchor of vaccinia virus (VV) hemagglutinin (HA), and the complete E7-coding sequence. The fusion gene was expressed under the HA late promoter by a recombinant VV, designated VV-E7-HA. The E7-HA protein was displayed on the surface of cells infected with the recombinant virus and was more stable than unmodified E7. The biological properties of the VV-E7-HA virus were compared with those of a VV-E7 virus that expressed the unmodified E7 and with a VV expressing the Sig-E7-LAMP fusion protein. While the first two of these recombinants were based on VV strain Praha, the third was derived from the WR strain of VV. Infection of mice with the VV-E7-HA virus induced the formation of E7-specific antibodies with the predominance of the IgG2a isotype, whereas the other two viruses did not induce the formation of E7-specific antibodies. Unlike the other two viruses, VV-E7-HA did not induce a response of cytotoxic T lymphocytes or Th1 cells and did not protect mice against the growth of E7-expressing tumors. Thus, VV-E7-HA induced a differently polarized immune response to the E7 protein than the other two viruses.
authors.affiliation: Department of Experimental Virology, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 12820 Prague 2, Czech Republic. sarkan@uhkt.cz
authors.forename: Sárka
authors.initials: S
authors.lastname: Nemecková
authors.forename: Růzena
authors.initials: R
authors.lastname: Stránská
authors.forename: Jana
authors.initials: J
authors.lastname: Subrtová
authors.forename: Luda
authors.initials: L
authors.lastname: Kutinová
authors.forename: Pavel
authors.initials: P
authors.lastname: Otáhal
authors.forename: Petr
authors.initials: P
authors.lastname: Hainz
authors.forename: Lucie
authors.initials: L
authors.lastname: Maresová
authors.forename: Vojtech
authors.initials: V
authors.lastname: Sroller
authors.forename: Eva
authors.initials: E
authors.lastname: Hamsíková
authors.forename: Vladimír
authors.initials: V
authors.lastname: Vonka
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D006389:Hemagglutinins, Viral / Q000276:immunology; D007111:Immunity, Cellular; D015847:Interleukin-4 / Q000096:biosynthesis; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000517:prevention & control; D009856:Oncogene Proteins, Viral / Q000032:analysis / Q000276:immunology*; D050725:Papillomavirus E7 Proteins; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000276:immunology; D014611:Vaccination; D014616:Vaccinia virus / Q000235:genetics; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D006389:Hemagglutinins, Viral; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D011993:Recombinant Fusion Proteins; D014765:Viral Vaccines; C059731:oncogene protein E7, Human papillomavirus type 16; D015847:Interleukin-4